A Study Of Docetaxel For Injection (Albumin Bound) In Patients With Advanced Pancreatic Cancer

Study Overview

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer

This study is a randomized, double-blind, multicenter, phase Ⅲ clinical study to compare the clinical efficacy and safety of Docetaxel for Injection (Albumin Bound) in combination with best supportive care versus placebo in combination with best supportive care in participants with pancreatic cancer who have received gemcitabine-containing and fluorouracil-containing regimens.

This study is a randomized, double-blind, multicenter, phase Ⅲ clinical study to compare the clinical efficacy and safety of Docetaxel for Injection (Albumin bound) plus best supportive care versus placebo plus best supportive care in participants with pancreatic cancer who have received a previous treatment regimen containing gemcitabine and fluorouracil. It is planned to enroll 142 participants, and participants will be randomized to receive Docetaxel for Injection (albumin bound) in combination with best supportive care or placebo in combination with best supportive care in a 2:1 ratio. Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.

Advanced Pancreatic Cancer

DRUG: Docetaxel for Injection (Albumin bound)
DRUG: Placebo
DRUG: Best supportive care

HB1801-011

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2024-06-24	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2024-07-02
First Submitted that Met QC Criteria 2024-07-02	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2024-07-09
First Posted (ACTUAL) 2024-07-09	Results First Posted N/A	Last Verified 2024-07

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Randomized

Interventional Model:
Parallel

Masking:
Quadruple

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Docetaxel for Injection (Albumin Bound) in combination with best supportive care Docetaxel for Injection (Albumin Bound) ：i.v., q3w,100mg/m^2； Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care	DRUG: Docetaxel for Injection (Albumin bound) Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks. DRUG: Best supportive care Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.
PLACEBO_COMPARATOR: Placebo in combination with best supportive care Placebo ：i.v., q3w； Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care	DRUG: Placebo Placebo was human blood albumin without the active ingredient docetaxel DRUG: Best supportive care Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Docetaxel for Injection (Albumin Bound) in combination with best supportive care

Docetaxel for Injection (Albumin Bound) ：i.v., q3w,100mg/m^2； Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care

DRUG: Docetaxel for Injection (Albumin bound)

Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.

DRUG: Best supportive care

Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.

PLACEBO_COMPARATOR: Placebo in combination with best supportive care

Placebo ：i.v., q3w； Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care

DRUG: Placebo

Placebo was human blood albumin without the active ingredient docetaxel

DRUG: Best supportive care

Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.

Primary Outcome Measures	Measure Description	Time Frame
OS	The overall survival (OS) of the two groups. All the participants received tumor assessment every 6 weeks according to RECIST1.1.	Up to approximately 2 years

Secondary Outcome Measures	Measure Description	Time Frame
PFS	All the participants received tumor assessment every 6 weeks according to RECIST1.1 to evaluate the progression-free survival (PFS) .	Up to approximately 2 years
ORR	All the participants received tumor assessment every 6 weeks according to RECIST1.1 to evaluate the objective response rate (ORR).	Up to approximately 2 years
DCR	All the participants received tumor assessment every 6 weeks according to RECIST1.1 to evaluate the disease control rate (DCR).	Up to approximately 2 years
DOR	All the participants received tumor assessment every 6 weeks according to RECIST1.1 to evaluate the duration of response (DOR).	Up to approximately 2 years
Incidence of AE and SAE	Incidence of AE and SAE	Up to approximately 2 years
PK	Plasma concentration of docetaxel (free and total)	At the end of Cycle 1(each cycle is 21 days)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Clinical Trials Information Group officer

Phone Number: 86-0311-69085587

Email: ctr-contact@cspc.cn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

1. Patients aged ≥18 years (subject to the date when the informed consent form is signed) and voluntarily signed the informed consent form.
2. Histologically or cytologically confirmed diagnosis of pancreatic cancer (including adenosquamous carcinoma).
3. Patients who have got disease progression or toxic intolerance after previous standard treatment (gemcitabine based and fluorouracil based therapy).
4. At least one evaluable lesion according to RECIST 1.1 .
5. Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
6. Patients with fine organ function (no medical supportive treatments such as blood component transfusion, growth factors within 2 weeks before taking the relevant inspections):

7. The patient must agree to take adequate contraception from signing of ICF through 6 months after last dose, women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose of the investigational drug.

1. Patients who have a history of severe allergy to any excipients of the investigational drug or taxanes，or known allergy and/or contraindications to glucocorticoids (including but not limited to active digestive tract ulcers, severe hypertension, severe hypokalemia, glaucoma, etc.).
2. Patients with partial or complete intestinal obstruction or complete biliary obstruction that cannot be relieved by active treatment.
3. Previous history of inflammatory bowel disease, chronic diarrhea, and gastrointestinal bleeding.
4. Patients who had a history of other active malignant tumors within 2 years before the first dose of the investigational drug, except for the study disease pancreatic cancer and curable cancer that had been cured (such as basal cell or squamous cell skin cancer, superficial bladder cancer, cervical cancer or breast cancer in situ that had been excised).
5. Patients with active hepatitis B (HBsAg and/or HBcAb positive but HBV DNA < 2000 IU/mL can be included), active hepatitis C (HCV antibody positive but HCV RNA negative can be included), and HIV antibody positive.
6. Adverse reactions from the previous anti-tumor treatment have not yet recovered to ≤ level 1 based on CTCAE 5.0 (except for alopecia, hyperpigmentation, or other toxicity without safety risk judged by the investigator).
7. Patients with a history of severe cardiovascular disease, including but not limited to:：

8. Patients with uncontrolled serous cavity effusion requiring frequent drainage or medical intervention (e.g., pleural effusion, abdominal effusion, pericardial effusion, etc., additional intervention was needed within 2 weeks after intervention, excluding exfoliative cytology testing of the exudate) within 2 weeks before the first dose of the investigational drug.
9. Patients with severe or active infections (including tuberculous infections) that require systemic antibacterial, antifungal, or antiviral therapy within 14 days before the first dose of the investigational drug, antiviral therapy for patients with viral hepatitis is permitted.
10. Received any anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) and any clinical trial intervention within 4 weeks prior to the first use of the investigational drug or within 5 half-lives of the most recently used anti-tumor drug (whichever is shorter), and used traditional Chinese medicine or proprietary Chinese medicine with anti-tumor indications within 14 days before the first use of the investigational drug.
11. Patients who have used potent inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of the investigational drug.
12. Patients who have undergone major surgery within 4 weeks before the first dose of the investigational drug and had not recovered sufficiently, or who need to undergo major surgery during the study.
13. Pregnant or nursing women.
14. Patients who is participating in another clinical study simultaneously unless it is an observational (non-interventional) clinical study or within the follow-up period of an interventional study.
15. Other situations that the investigator considers not suitable for participating in the clinical study, including but not limited to: the patient is complicated by severe or uncontrolled medical conditions, which will increase the safety risk, interfere with the interpretation of study results or affect the study compliance.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record